What the FDA labels say about taking them together
Dutasteride and finasteride
Dutasteride's FDA label of September 11, 2025 names finasteride in its warnings and precautions section, and finasteride's label names dutasteride too. The finasteride label: “… 4-year placebo-controlled clinical trial with another 5α-reductase inhibitor (dutasteride, AVODART).”
Check it at the source: the dutasteride FDA label on DailyMed (effective September 11, 2025, Aurobindo Pharma Limited); the finasteride FDA label on DailyMed (effective March 18, 2026, Organon LLC).
What does the dutasteride label say about finasteride?
Dutasteride label, warnings and precautionsIn a 7-year placebo-controlled clinical trial with another 5 alpha-reductase inhibitor (finasteride 5 mg, PROSCAR ® ), similar results for Gleason score 8 to 10 prostate cancer were observed (finasteride 1.8% versus placebo 1.1%).
Source: FDA drug label (Dutasteride), Aurobindo Pharma Limited, effective September 11, 2025 (SPL set b32611f3-50ec-45bb-a671-ea10cec7829d), via openFDA; the full label on DailyMed
What does the finasteride label say about dutasteride?
Finasteride label, warnings and precautionsRisk of High-Grade Prostate Cancer Men aged 55 and over with a normal digital rectal examination and PSA ≤3.0 ng/mL at baseline taking finasteride 5 mg/day in the 7-year Prostate Cancer Prevention Trial (PCPT) had an increased risk of Gleason score 8-10 prostate cancer (finasteride 1.8% vs placebo 1.1%). [See Indications and Usage (1.3) and Adverse Reactions (6.1) .] Similar results were observed in a 4-year placebo-controlled clinical trial with another 5α-reductase inhibitor (dutasteride, AVODART) (1% dutasteride vs 0.5% placebo).
Propecia label (Organon LLC, October 14, 2024), warnings and precautionsRisk of High-Grade Prostate Cancer with 5α-Reductase Inhibitors Men aged 55 and over with a normal digital rectal examination and PSA ≤3.0 ng/mL at baseline taking finasteride 5 mg/day (5 times the dose of PROPECIA) in the 7-year Prostate Cancer Prevention Trial (PCPT) had an increased risk of Gleason score 8-10 prostate cancer (finasteride 1.8% vs placebo 1.1%). [See Adverse Reactions (6.1). ] Similar results were observed in a 4-year placebo-controlled clinical trial with another 5α-reductase inhibitor (dutasteride, AVODART) (1% dutasteride vs 0.5% placebo).
Source: FDA drug label (Propecia, NDA020788), Organon LLC, effective October 14, 2024 (SPL set 6f904709-65aa-44ce-b144-b4c8a0416e36), via openFDA
Source: FDA drug label (PROSCAR), Organon LLC, effective March 18, 2026 (SPL set 6f988153-fc74-4ca4-b29a-111f750c4a4b), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dutasteride | Finasteride | |
|---|---|---|
| Labeled for | Enlarged prostate (BPH) | Enlarged prostate (BPH) |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.157 per capsule 0.5 mg capsule | $0.0688 per tablet 5 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once